Literature DB >> 26018693

18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas.

Pierpaolo Alongi1, Lucia Zanoni, Elena Incerti, Federico Fallanca, Paola Mapelli, Nikolaos Papathanasiou, Luigi Gianolli, Maria Picchio, Jamshed Bomanji.   

Abstract

PURPOSE: The purpose of this study was to evaluate the performance and possible prognostic value of early (18)F-FDG PET/CT (FDG PET/CT) assessment after radiotherapy (RT) in patients with solitary bone plasmacytoma (SBP).
METHODS: Twenty-one patients affected by SBP who underwent FDG PET/CT scan for early restaging (≤6 months) postradiotherapy assessment were selected from the PET databases of University College London Hospital of London and San Raffaele Hospital of Milan. Patients with no abnormal uptake were classified as having no pathologic uptake (NPU). A SUV(max) cutoff value of 4 was chosen to discriminate minimal residual uptake (MRU; SUV(max) ≤ 4) from pathologic uptake (PU, SUV(max) >4). Progression-free survival (PFS) rate was estimated using Kaplan-Meier curves and Cox regression analysis.
RESULTS: In 10 of 21 patients restaged by FDG PET/CT, further previous baseline scan was available also at staging, and results showed positive findings at the level of all biopsy-proven disease areas.Considering MRU as PU, FDG PET/CT showed a sensitivity and specificity of 86% and 29%, respectively. Using SUV(max) >4 as the cutoff, sensitivity and specificity were 86% and 93%, respectively. Kaplan-Meier curves revealed a significant difference in PFS probability between patients classified as positive on FDG PET/CT using a cutoff of SUV(max) >4 (PU) and those classified as negative (NPU + MRU) (log-rank, Mantel-Cox, P = 0.009; χ(2) = 6.85). Cox regression analysis of PFS using SUV(max) >4 as cutoff revealed an interesting relation in prediction of progression (HR, 9.458).
CONCLUSION: (18)F-FDG PET/CT for early restaging after RT in patients with SBP should be considered carefully in view of the lack of specificity of a low SUV(max) value. The good correlation between a high SUV(max) value and follow-up suggests a possible prognostic role for FDG PET/CT in disease progression at early restaging after RT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26018693     DOI: 10.1097/RLU.0000000000000819

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.

Authors:  Domenico Albano; Giovanni Bosio; Giorgio Treglia; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

3.  PET/CT-negative malignant spine tumor with pathologic fracture: A case report of malignant solitary bone plasmacytoma.

Authors:  Kang-Un Kim; Joon Hyuk Choi; Gun Woo Lee
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

4.  The role of initial 18F-FDG PET/CT in the management of patients with suspected extramedullary plasmocytoma.

Authors:  Linqi Zhang; Xu Zhang; Qiao He; Rusen Zhang; Wei Fan
Journal:  Cancer Imaging       Date:  2018-05-15       Impact factor: 3.909

5.  Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era.

Authors:  F A Sharpley; P Neffa; F Panitsas; J Kothari; M Subesinghe; D Cutter; R Shcolnik Szor; G Aparedcida Martinez; V Rocha; K Ramasamy
Journal:  PLoS One       Date:  2019-07-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.